Literature DB >> 18588566

Serum vascular endothelial growth factor and sublingual immunotherapy.

G Ciprandi1, B M Colombo, G Murdaca, M De Amici.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18588566     DOI： 10.1111/j.1398-9995.2008.01727.x

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  5 in total

1.  Sub-lingual immunotherapy: world allergy organization position paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2009-11-19       Impact factor: 4.084

Review 2.  Free radicals and endothelial dysfunction: potential positive effects of TNF-α inhibitors.

Authors:  Giuseppe Murdaca; Francesca Spanò; Paola Cagnati; Francesco Puppo
Journal:  Redox Rep       Date:  2013-05-10       Impact factor: 4.412

Review 3.  Role of bevacizumab in colorectal cancer growth and its adverse effects: a review.

Authors:  Efstathios T Pavlidis; Theodoros E Pavlidis
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

Review 4.  Long-term treatment of rheumatoid arthritis with adalimumab.

Authors:  Giuseppe Murdaca; Francesca Spanò; Francesco Puppo
Journal:  Open Access Rheumatol       Date:  2013-05-07

5.  Evaluation of circulating vascular endothelial growth factor and its soluble receptors in patients suffering from persistent allergic rhinitis.

Authors:  E Koczy-Baron; A Grzanka; J Jochem; R Gawlik; A Kasperska-Zajac
Journal:  Allergy Asthma Clin Immunol       Date:  2016-04-27       Impact factor: 3.406
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.